Is it fair for social media to play a role in determining which patients get access to experimental treatments?
Can rescuing individual patients in need be reconciled with an evidence-based regulatory approval process for new therapies?
And, if there is a duty to “rescue” terminally ill patients by paying for access to experimental therapies who has that obligation?
Dr. Caplin addresses these questions in this lecture.
This program is part of Baruch College's Ethics Week 2015.